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Abstract: 
The pharmacological disruption of the interaction between the HIV Tat protein and its cognate 
transactivation response RNA (TAR) would generate novel anti-viral drugs with a low 
susceptibility to drug resistance, but efforts to discover ligands with sufficient potency to warrant 
pharmaceutical development have been unsuccessful. We have previously described a family of 
structurally constrained β-hairpin peptides that potently inhibits viral growth in HIV-infected 
cells. The NMR structure of an inhibitory complex revealed that the peptide makes intimate 
contacts with the three-nucleotide bulge and the upper helix of the RNA hairpin, but that a single 
residue contacts the apical loop where recruitment of the essential cellular co-factor cyclin T1 
occurs. Attempting to extend the peptide to form more interactions with the RNA loop, we 
examined a library of longer peptides and achieved >6-fold improvement in affinity. The 
structure of TAR bound to one of the extended peptides reveals that the peptide slides down the 
major groove of the RNA, relative to our design, in order to maintain critical interactions with 
TAR. These conserved contacts involve three amino acid side chains and identify critical 
interaction points required for potent and specific binding to TAR RNA. They constitute a 
template of essential interactions required for inhibition of this RNA. 
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Introduction 
HIV-1 TAR is a stem loop RNA found at the 5’ end of all nascent viral transcripts (Figure 1). 
The cooperative binding of the viral protein Tat and its cellular co-factor cyclin T1 to TAR 
recruits and activates the CDK9 kinase to hyperphosphorylate RNA polymerase II, leading to 
greatly enhanced processivity of the polymerase (1,2). If the Tat-TAR-cyclin complex does not 
form, the polymerase produces primarily short transcripts and viral replication is inefficient. In 
the past decade or two, many groups have identified small molecule and peptide mimetic ligands 
for TAR (3-19), but none had sufficient potency and specificity to warrant pharmaceutical 
development. We have previously used structure-based design methods to discover cyclic 
peptide structural mimics of Tat protein with nM affinity for HIV TAR (20-23). These molecules 
inhibit viral replication in primary human lymphocytes with activity only 10-fold lower than the 
non-nucleoside reverse transcriptase inhibitor nevirapine (manuscript in preparation). They are 
active against viral isolates from each of the HIV-1 clades and are not cytotoxic to at least 1 mM 
concentrations. The peptides are confined to their cyclic β-hairpin structure by a D-Pro-L-Pro 
hairpin-promoting template (24). Their constrained cyclic structure stabilizes them against 
proteolysis, and mechanistic studies show that the compounds inhibit early steps in reverse 
transcription as well as Tat-dependent HIV transcription (manuscript in preparation). These 
characteristics make the peptides exciting antiviral leads, but their activity must be improved 
before they can be further explored as drug candidates. 
 The NMR structure of the lead peptide L-22 (Table 1, Figure 2a) bound to TAR has been 
reported (23). It reveals that the peptides bind TAR in the major groove of the upper RNA helix 
(nucleotides 26-29 and 36-39) with the D-Pro-L-Pro template facing down towards the lower 
helix. Interactions important for peptide affinity and selectivity can be grouped into three 
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categories: stacking with residue A35 of the apical loop of TAR that wraps the RNA around the 
solvent-exposed face of the peptide; hydrophobic contacts that drive formation of a base triple 
between bulge residue U23 and base pair A27-U38 in the upper helix; and the stabilization of the 
base triple by charged residues binding near the interhelical junction. Based on these features, we 
hypothesized that the peptide binding activity could be improved by lengthening the β-hairpin to 
establish more extensive contacts with the apical loop of the RNA. 
 In order to test this hypothesis, we synthesized a small library of 25 peptides containing 
1, 2 or 4 additional amino acids and tested their binding to TAR RNA. Successful motifs were 
combined in a follow-up library of 12 peptides. One of these peptides, KP-Z-41, emerged as the 
lead molecule among these extended peptides due to its affinity for TAR and the quality of NMR 
data for its complex with TAR RNA. We determined the structure of this complex by NMR and 
observed that contacts near the interhelical junction remain almost unchanged between this 
structure and our previous L-22 structure, while the contacts to the loop and RNA backbone re-
position themselves to accommodate the interactions at the junction. This was unexpected from 
our structure-based design, and this interaction positions the peptide further down the major 
groove, away from the apical loop, than we had predicted. Thus, while we were unsuccessful in 
extending the peptide toward the apical loop, the structure identifies a small set of essential 
interactions that are critical for recognition of HIV-1 TAR and could be exploited for the design 
of small molecule peptidomimetics. 
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Methods 
Peptide and RNA synthesis - The synthesis of the cyclic peptides was conducted as described 
previously (20,22). HIV-1 TAR RNA was prepared in vitro from commercially synthesized 
DNA templates (IDT) using in house purified T7 RNA polymerase and unlabeled nucleotides 
(Sigma), or 98% 15N, 13C labeled nucleotides (Cambridge Isotope Labs), or 98% deuterated 
nucleotides (Isotec). RNA products were separated by denaturing polyacrylamide gel 
electrophoresis. The desired RNA was excised from the gel and further purified by 
electroelution, desalting on a NAP-10 column (GE Healthcare), and extensive dialysis against a 
10 mM potassium phosphate buffer, pH 6.6, with 0.1 mM EDTA (25,26). Prior to NMR, RNA 
products were exchanged into 99.99% D2O by lyophilization, and then annealed with heating to 
90 °C and quick cooling on ice. 
Preparation of radiolabeled RNA and gel shift assays – T4 RNA ligase (Promega) and cytidine 
3',5'-bis[alpha-32P]phosphate, triethylammonium salt (pCp, GE Healthcare) were used to label 
purified HIV-1 TAR RNA. Free pCp remaining in solution after the ligation was largely 
removed by passing the RNA solution through a NAP-10 desalting column (GE Healthcare). The 
RNA was annealed by heating to 90 °C, followed by quick cooling on ice. For each gel shift 
assay, peptides were incubated on ice for 30 minutes with labeled TAR and assay buffer (0.05 M 
Tris-HCl, 0.05 M KCl, 0.2 M DTT, 1% Triton X-100, and tRNA at 10 mg/mL). Samples were 
then fractionated by native PAGE at 15W and 4 °C in 0.5X TB buffer. Dried gels were exposed 
to a phosphor imaging plate and viewed with a Molecular Dynamics scanner. Images were 
analyzed with ImageQuant software. 
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NMR Spectroscopy and Spectral Assignments - NMR spectra were collected on Bruker 500 and 
600 MHz  spectrometers equipped with cryo-cooled probes. Data were processed with NMRPipe 
(27) and analyzed in Sparky (28). NOESY experiments were recorded at multiple mixing times 
(80-300 ms) at either 25 °C (D2O) or 4 °C (H2O). The 2D 13C filtered NOESY and TOCSY 
spectra of the “F1fF2f” type (29) were collected to facilitate assignments of peptide resonances. 
Spectra using partially perdeuterated RNA (with only H6/8, H2, H1’, and H2’ protons present) 
had sharper line widths that facilitated NOE assignments (SI Figure 1). Resonance assignments 
started from those already available for the previous L-22/HIV-1 TAR RNA complex (23) and 
were extended to this new complex using HCCH-COSY, HCCH-TOCSY, and HSQC-NOESY 
experiments. Initial proton assignments for the peptide were made from F1fF2f NOESY spectra 
and based on the observation of the typical Hα(i) to HN(i+1) pattern of NOEs common in β-
sheets, then completed with the partially perdeuterated RNA that removed much of the overlap 
between peptide and sugar resonances. 
 
Structure Determination - Structures of the HIV-1 TAR RNA/KP-Z-41 complex were calculated 
with Xplor-NIH (30) using the experimental restraints summarized in Table 3. Loose restraints 
on backbone dihedral angles (+/- 40°) were introduced for base-paired regions in both helical 
stems based upon unambiguous spectroscopic verification of an A-form RNA conformation as 
determined from the pattern of cross-peaks in TOCSY and NOESY spectra (25), while backbone 
dihedral angle restraints for the peptide were derived with TALOS (31). The final 10 converged 
structures of the complex were selected from the population of structures with no NOE restraint 
violations greater that 0.5 Å and had the lowest violations of all experimental restraints. 
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Results 
Based on the interactions between the peptide and TAR observed in our previous peptide 
structure and the results of our mutational studies, we synthesized a small library of new peptides 
containing 1, 2 or 4 additional amino acids. Selected peptides from this initial set are listed in 
Table 2 and are named KP-Z-01 through KP-Z-22 for ease of reference. All peptides were 
cyclized using the D-Pro-L-Pro template, and the majority of these new peptides incorporate two 
central cysteine residues forming a disulfide bridge to further stabilize the hairpin fold. Peptides 
were tested by electrophoretic mobility shift assay (EMSA) in the presence of 10,000-fold excess 
tRNA to establish their affinity and selectivity for TAR RNA. Peptides containing 16 and 18-
amino acids were more successful than those containing 15 amino acids, of which three out of 
four peptides showed no affinity for TAR even at the highest concentration tested (5 µM). This 
result can confidently be attributed to less stable β-hairpin formation in the cyclic peptides 
containing an odd number of residues. Previous NMR studies of our initial β-hairpin peptides 
have shown that stability of the hairpin in solution is necessary to observe strong affinity for 
TAR (20,22). Even the 16-amino acid peptides bound with only high nM affinity to TAR; this 
represented a significant loss of activity from our previous success with L-22. It was also 
disappointing to see that even significant changes in sequence resulted in minimal changes in 
affinity. For example, swapping the K-R-K motif near the hairpin turn of KP-Z-16 for R-K-R in 
KP-Z-17 changed the affinity of the peptide by less than two-fold. Even exchanging residues 
across the hairpin (compare for example KP-Z-19 and KP-Z-20) yielded almost no change in 
affinity. These results suggest that binding of the 16-amino acid peptides may be largely charge-
mediated and is not likely to be very selective. 
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In the case of the 18-amino acid peptides, many encouragingly showed mid-nanomolar 
activity, even in the presence of a 10,000-fold excess of tRNA. Furthermore, small changes in 
sequence yielded significant changes in activity against TAR in some cases, indicating specific 
binding for this group of peptides. For example, the difference between KP-Z-05 and KP-Z-06 is 
only an exchange of residues at positions 6 and 7, but this rather small change alters binding 
from 150 nM to undetectable at the highest concentration tested (>5 µM). A similar change from 
KP-Z-10 to KP-Z-11 yields a comparable result. The sequence of KP-Z-02, one of the most 
successful peptides from the library, has an Arg-DArg motif at positions 7 and 8; changing these 
Arg to Leu-Lys in KP-Z-01 abolishes binding even at the highest concentration tested. 
Encouraged by the specific binding suggested by these results, we decided to pursue the 
optimization of the 18-amino acid peptides by rational design. Successful motifs from these 
peptides and the reported L-22/TAR structure were combined in a small follow-up library (Table 
2, KP-Z-33 through KP-Z-40). One of these peptides, KP-Z-40, emerged as the most potent 
peptide with an apparent binding constant of 25 nM, when measured in the presence of 10,000 
fold excess of tRNA competitor, and Kd <1 nM (when measured in a direct binding assay in the 
absence of any tRNA). This result represents a >6-fold improvement in affinity over the previous 
lead peptide L-22. 
The structure of L-22 showed that the Ile methyl groups on one face of the peptide were 
important for locking the peptide in the major groove of TAR (23). With this in mind, we 
designed a new peptide KP-Z-41, based on the sequence of KP-Z-40 but with an additional Ile at 
position 12 in place of the Ala found in the original peptide. The affinities of KP-Z-40 and KP-Z-
41, determined by EMSA (Figure 3) were similar, but the NOESY experiments for KP-Z-41 
revealed a much greater number of intermolecular NOEs. For this reason, the KP-Z-41/TAR 
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complex was selected for structure determination to better understand how increased affinity was 
obtained. 
 
Hydrophobic interactions promote formation of a base triple and anchor the peptide in the major 
groove: The structure contains a base triple between bulge residue U23 and the A27/U38 base 
pair, as also observed for L-22. The NOE data indicate a canonical pairing for U23 and A27 in 
the base triple; both A27 amino hydrogen atoms are protected from solvent exchange and 
observable in NOESY experiments. Formation of the base triple upon binding is likely driven by 
burial of the Ile12 methyls against U23, analogous to the interactions of Ile10 in the L22-TAR 
complex (Figure 4a) and Ile79 in our original model system of BIV Tat/TAR (21). Ile14 is also 
protected from solvent by burial in the major groove, similar to Ile12 in the L-22 peptide. 
Placement of these large hydrophobic side chains on the peptide backbone orients the 
correct face of the peptide towards the RNA and induces formation of the base triple; thus, 
location of the hydrophobic residues on the peptide is one of the most crucial elements for 
affinity to the TAR. The peptide KP-Z-41 contains three isoleucine residues at positions 12, 14, 
and 16. However, only Ile12 and Ile14 are located in the RNA major groove, forcing the D-Pro-
L-Pro end of the template to extend away from the RNA into solution. We had originally 
hypothesized that Ile14 and Ile16 would be the hydrophobic groups docked in the major groove 
near the base triple, with Ile12 and the Lys8-Gly9 turn extending up the groove toward the apical 
loop instead. However, the structure reveals that, while burial of these hydrophobic groups is 
important for orienting the correct face of the peptide toward the RNA, their placement within 
the structure is also governed by key peptide-RNA polar interactions, as discussed below. In 
order to form these polar interactions at the inter-helical junction, the peptide must slide down 
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the major groove relative to our design, leaving Ile12 and Ile 14 docked in the pocket formed in 
the major groove upon peptide binding.  
 
Interactions between polar side chains and the bulge region of TAR position the peptide relative 
to the RNA: Two important interactions between polar side chains and the RNA can be seen near 
the TAR bulge. The guanidinium group of Arg7 lies over U23 and stabilizes the base triple 
(Figure 4b). At the same time, the charged terminus of Lys8 is favorably oriented by the 
positioning of Arg7 and anchor residue Ile12 (as discussed above) toward a pocket of negative 
charge formed by the phosphate groups of nucleotides C24 through G28 at the interhelical 
junction (Figure 4c). The roles of Arg7 and Lys8 in KP-Z-41 are nearly identical to those of 
Arg5 and Lys6 in L-22. This Arg-Lys combination, along with the hydrophobic residue buried 
beside the base triple, appear to be the best maintained features between the two structures. Other 
interactions adjust themselves to keep these contacts intact. These two polar interactions alter the 
way the peptide contacts the apical loop, as discussed in the following section, and force the D-
Pro-L-Pro motif and adjacent residues to slide down the major groove and extend away from the 
RNA, contrary to what we had expected in the rational design of the longer peptide library. 
 
The cyclic peptide contacts the apical loop of TAR in a novel manner: A promising feature of 
these β-hairpin peptides for RNA specificity is their ability to simultaneously contact multiple 
unique secondary structure elements of the RNA. In the L-22/TAR complex, the Arg11 
guanidinium group stacks on the base of loop residue A35, and this interaction pulls the apical 
loop to partially close around the RNA. An interaction with A35 is present for KP-Z-41 as well, 
but the contact is different, because the space occupied by Arg11 in the L-22 peptide is replaced 
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by a Cys in KP-Z-41. Nevertheless, the contact to the loop is of such importance that the RNA 
adjusts itself to maintain the interaction. Instead of  direct stacking between A35 and an arginine 
residue, the base of G34 is flipped out from the rest of the RNA and sandwiched between A35 
and Arg11 of KP-Z-41 (Figure 4d). In this new arrangement, G34 completes the Arg-A35 
interaction previously seen in L-22.  
 
Comparison of NOESY data for complexes of lead peptides KP-Z-40 and KP-Z-41 with HIV-1 
TAR RNA: As mentioned previously, cyclic peptide KP-Z-40 has the strongest affinity for the 
TAR RNA based on EMSA results, but the NOE data for this peptide-RNA complex were of 
lower quality than for KP-Z-41, so that the latter peptide was selected for structure 
determination. Comparison of the intermolecular NOEs for both complexes reveals strong 
similarities for cross-peaks defining the peptide contact to the apical loop. Specifically, NOEs 
between Val2 and A35, Arg10 and G34, and Arg11 and G34 are present for both complexes. 
These pairings represent several of the most intense intermolecular NOEs for the KP-Z-40/HIV-
1 TAR complex. From this NOE comparison, we conclude that the peptides bind to the RNA in a 
similar manner. However, without a structure for both peptides, it is difficult to conclusively 
identify the structural or dynamics basis for the difference in activity between the two peptides. 
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Discussion: 
The Tat-TAR interaction has long been considered a target for the development of novel 
antivirals but the difficulty of inhibiting RNA-protein interfaces with small molecules has 
prevented the successful pre-clinical or clinical development of Tat-TAR inhibitors (3-19,32-34). 
To overcome these difficulties, our group has focused on cyclic β-hairpin peptide mimics of Tat 
protein, developed through a structural rationale (20-23,35). We reasoned that the rigidity of 
these pre-structured peptides would increase their selectivity, compared to other flexible RNA-
binding peptide mimics (3,4), and their larger molecular weight would allow more potent and 
specific interactions compared to small organic structures. Based on this rationale, we succeeded 
in developing cyclic peptide structural mimics of Tat protein with nM affinity for HIV TAR and 
with an in vivo activity that makes them attractive antiviral leads (22,23). In order to further 
improve their potency, we extended them by 1, 2, or 4 amino acids, reasoning that a longer 
hairpin would make more extensive contacts with the single-stranded nucleotides in the apical 
loop than we had previously observed in the structure of a lead peptide-RNA complex (23). 
Some of the new peptides (Table 2) were found to bind tightly to HIV-1 TAR, but only when the 
hairpin was extended by 4 amino acids. For this group of molecules, even small variations in the 
peptide sequence led to relatively large changes in activity, suggesting a specific interaction. The 
specificity of the peptides for HIV TAR RNA is also demonstrated by their ability to retain 
strong affinity for the target even in the presence of very large excess of tRNA. Furthermore, 
when we compared binding for other members of this family of cyclic peptides with various 
mutated versions of HIV TAR, including mutation and deletion of residues U23 and A35, we 
demonstrated that the absence of a single critical nucleotide abolishes peptide activity, lending 
additional evidence for the specificity of these peptides (23)
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designed based on the features of the more active library members, and a molecule, KP-Z-41, 
emerged with sub-nanomolar affinity for HIV-1 TAR. An improvement >6-fold was thus 
successfully obtained in binding activity. 
 We determined the structure of the KP-Z-41/TAR complex in order to verify whether our 
rationale of extending the peptide to interact with the loop was correct and to guide our next 
steps of peptide development. We were surprised to discover that the additional residues did not 
bring the peptide closer to the loop; instead, the D-Pro-L-Pro end of the peptide hairpin extended 
away from the RNA into solution. The structural reasons for this effect were nonetheless very 
revealing. Interactions between the peptide and the RNA interhelical junction are nearly identical 
for KP-Z-41 and the previous lead peptide L-22, at residues Arg7, Lys8, and Ile12. In order to 
form these interactions, however, the peptide slides down the major groove away from the apical 
loop and pushes residues near the D-Pro-L-Pro template into solution. Not only are the peptide-
RNA interactions at Ile12, Arg7 and Lys8 preferably formed over other possible interactions 
near the D-Pro-L-Pro end of the peptide; they are apparently favorable enough to drive the 
increased affinity of the peptide for the RNA despite the entropic costs of leaving several 
hydrophobic residues (an isoleucine and both prolines) exposed to solvent. The placement of 
these three critical residues (Ile12, Arg7 and Lys8) should be regarded as the minimum 
requirement for peptide mimics of Tat targeting this HIV TAR conformation. Their requirement 
to organize the RNA-peptide complex will be taken into account in our future peptide designs 
and should be considered when designing small molecule ligands for TAR as well.  
Because of these unexpected changes in the peptide-RNA interactions, Arg10 and Arg11 
are the only residues in the KP-Z-41/TAR structure positioned near the loop, and only Arg11 
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forms a stable enough interaction to be detected by NOESY experiments, stacking over G34 and 
A35. The placement of the disulfide bridge used for reinforcing hairpin formation in KP-Z-41 
prohibits the direct arginine stacking with RNA residue A35 that was seen in the L-22/TAR 
structure. Thus, interactions of the amino acids at the C-terminal side of the KG turn are fairly 
weak and should be optimized further to improve peptide binding. Our future work on peptide 
design will focus on development of new contacts at the apical loop based on re-organization of 
the peptide, while maintaining features that are shown in this study to be crucial for specific HIV 
TAR binding. By fully understanding the essential hydrophobic and polar interactions that lead 
to strong binding activity, we should now be able to design intermolecular contacts at other 
locations in our peptide. By moving the crucial Ile-Arg-Lys combination to new locations within 
the peptide, we may be able to induce the peptide to slide upwards along the major groove and 
reach the apical loop of the RNA to form more extensive contacts.  
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Figure Captions 
Figure 1:  (a) Sequence and secondary structure of the HIV-1 TAR RNA construct used in these 
studies, numbered according to the start of transcription of the viral RNA, and (b) sequences of 
the lead peptides L-22 and KP-Z-41 (LP = L-Pro and DP = D-Pro). The dotted line indicates a 
disulfide bridge. 
 
Figure 2: (a) Structures of the HIV-1 TAR/L-22 complex (left) and the HIV-1 TAR/KP-Z-41 
complex (right). The sequences of the cyclic peptides are shown in Figure 1. The orientation of 
the peptide in the RNA major groove is the same in both structures. Common interaction sites 
are highlighted with arrows: the lysines that point toward the interhelical junction (black), the 
arginines that stack over the base triple (red), and the isoleucines that anchor the peptide in the 
major groove (blue). b) Superposition of ten lowest energy structures for the RNA (left) and 
cyclic peptide (right): guanosines are in purple, cytosines in black, adenosines in red, uracils in 
gray, and the peptide is in orange. 
 
Figure 3: Comparison of binding results for several peptides from the KP-Z library (all 
concentrations are in nM) to HIV TAR (1 nM) by electrophoretic mobility shift assay (EMSA); 
the buffer contains a 10,000 fold excess of tRNA to disfavor binding of peptides that form non-
specific interactions. 
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Figure 4: a) Comparison of the hydrophobic interactions observed in the HIV-1 TAR/KP-Z-41 
complex (top) and in the HIV-1 TAR/L-22 complex (bottom) that stabilize the U23-A27-U38 
base triple. The peptide L-22 penetrates deeper into the major groove compared to KP-Z-41, and 
thus the Ile residue in L-22 is in closer proximity to the base triple than in KP-Z-41. The RNA is 
represented as a gray surface with nucleotides of interest in purple, the peptide is in orange, and 
the Van der Waals surface of the Ile side chain is represented in dots. b) An arginine 
guanidinium group stacks on top of the U23 base to provide a cation-π interaction that stabilizes 
the base triple in both the KP-Z-41/TAR complex (top) and the L-22/TAR complex (bottom). c) 
The charged terminus of Lys8 is oriented toward a pocket of negative charge formed by the 
phosphate groups of nucleotides C24 through G28 at the interhelical junction. d) The direct 
stacking between A35 and an arginine residue that is seen in the L-22/TAR complex (bottom) is 
replaced in this new complex by a different set of loop-peptide interactions.  The base of G34 is 
instead flipped out from the RNA loop and sandwiched between A35 and Arg11 in the KP-Z-
41/TAR complex (top). 
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Table Captions    
Table 1: Sequences of the lead peptides L-22 and KP-Z-41 and summary of their binding 
activities against HIV-1 TAR RNA (Kd values are in nM), as determined by EMSA in the 
absence of competitor tRNA. Residues are aligned in the table to represent similarity in position 
upon binding HIV-1 TAR. 
 
Table 2: Sequences of selected peptides and summary of their activities against HIV-1 TAR 
RNA (Kd values are in nM), as determined by EMSA in the presence of competitor tRNA. All 
peptides are cyclized with a D-Pro-L-Pro motif not listed here to simplify the table. Lower-case 
letters indicate D-amino acids. 
 
Table 3: Experimental restraints and structural statistics for structure determination of the KP-Z-
41/TAR complex. 
 
 
 
